Clinical trials: Horton Disease
Giant Cell Arteritis, Temporal Arteritis
Early Temporal Dynamics of Optic Nerve Sheath Diameter After Therapy in GCA
Giant cell arteritis (GCA) is an inflammatory disease of large and medium arteries that can cause irreversible vision loss. Glucocorticoids (GCs) rapidly suppress inflammation, but diagnostic imaging tests such as temporal artery…
- Conditions
- Giant Cell Arteritis, Temporal Arteritis, Optic Nerve Diseases, Diagnosis
- Trial name
- SONIC-TIME (NCT07508514)
- Testing
- Optic Nerve Sheath Ultrasound, Temporal artery ultrasound, Bloodwork : CRP and ESR
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Giant Cell Arteritis, Large Vessel Giant Cell Arteriitis
Longitudinal Imaging in Patients With Large Vessel Vasculitis to Predict Further Disease Course
Longitudinal imaging in patients with large vessel vasculitis to predict further disease course
- Trial name
- NCT04204876
- Testing
- Magnet Resonance Imaging (MRI), PET/CT analysis
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- University Hospital, Basel, Switzerland
Giant Cell Arteritis
Post-therapeutic Imaging Evaluation of Patients With Horton's Disease (Giant Cell Arteritis) (EvHortim)
Giant cell arteritis (GCA), also known as Horton's disease, is an inflammatory arteritis of the large and medium-sized arteries, with an estimated incidence of 17.8/100,000 in people over 50.
- Trial name
- EvHortim (NCT06004154)
- Testing
- Injected cerebral MRI angiography and ultrasound of the superior aortic trunks, temporal and axillary arteries
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Giant Cell Arteritis, Polymyalgia Rheumatica
Clinical and Immunogenetic Characterization of Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR)
A multi-centre observational study recruiting prospective and retrospective cohorts of patients with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA).
- Trial name
- NCT04102930
- Where
- 76 sites in United Kingdom
- Volunteers
- 4,500 people
- Sponsor
- University of Leeds
Polymyalgia Rheumatica, Giant Cell Arteritis
Improved Diagnostics and Monitoring of Polymyalgia Rheumatica
Background: Polymyalgia rheumatica (PMR) is characterised by pain of the proximal muscles, general symptoms, and raised inflammatory markers. Treatment with prednisolone has several adverse effects.
- Conditions
- Polymyalgia Rheumatica, Giant Cell Arteritis, Adrenal Insufficiency
- Trial name
- NCT04519580
- Testing
- PET/CT
- Where
- 3 sites in Denmark
- Volunteers
- 98 people
- Sponsor
- Kresten Krarup Keller
Giant Cell Arteritis (GCA), Spondylarthritis
Study of the Association Between Sacroiliitis/Axial Spondylarthritis and Giant Cell Arteritis/ Polymyalgia Rheumatica
The purpose of the study is to recruit as many patients as possible presenting with sacroiliitis or authentic axial spondylarthritis and giant cell arteritis.
- Conditions
- Giant Cell Arteritis (GCA), Spondylarthritis, Polymyalgia Rheumatica
- Trial name
- SAGE PPR (NCT07394478)
- Testing
- Description of population
- Where
- 2 sites in France
- Volunteers
- 10 people
- Sponsor
- Hôpital NOVO
Giant Cell Arteritis, Tomography, Optical Coherence
Histopathological Analysis of Temporal Artery Biopsy Following Dynamic Full-field Optical Coherence Tomography, a Comparison to Conventional Histopathological Findings in Patients With Suspected Giant Cell Arteritis (DOCTA)
Giant cell arteritis (GCA) is a type of large vessel granulomatous vasculitis responsible for the inflammation of the aorta and the branches of the external carotid, notably temporal arteries.
- Trial name
- DOCTA (NCT05663333)
- Testing
- Dynamic full-field optical coherence tomography analysis of temporal artery biopsy
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Centre Hospitalier William Morey - Chalon sur Saône
Horton Disease
Interest of Medical Imaging in the Diagnostic Strategy Vis a Vis a Suspected Horton Disease
The study aims at measuring the sensitivity and specificity of a series of imaging signs (recorded by magnetic resonance angiography, vascular tomodensitometry, vascular ultrasonography, retina angiography and retina optic…
- Trial name
- HORTIM (NCT02473029)
- Testing
- Vascular tomodensitometry, Magnetic resonance angiography, Vascular ultrasonography
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Vasculitis, Diagnoses Disease
CXCR4-PET/CT for Diagnosing Giant Cell Arteritis
Giant cell arteritis (GCA) is the most common vasculitis in the elderly. Accurate diagnosis is of utmost importance in order to then initiate the necessary immunosuppressive therapy.
- Trial name
- NCT05604482
- Testing
- CXCR4-PET
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Matthias Fröhlich
Giant Cell Arteritis
Investigation of the Influence of the Human Microbiome on Giant Cell Arteritis
The longitudinal observational study aims to assess the impact of the microbiome especially the gut-microbiome in the emergence and course of giant cell arteritis (abbr. GCA) patients.
- Trial name
- GCA-Biom (NCT06279065)
- Testing
- Analysis of blood and microbiome samples (stool, oral lavage)
- Where
- 2 sites in Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Bonn
Polymyalgia Rheumatica
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)
The purpose of this study is to demonstrate the efficacy and safety of secukinumab 300 milligram (mg) and 150 mg administered subcutaneously (s.c.) for 52 weeks in combination with prednisone tapered over 24 weeks in adult…
- Trial name
- REPLENISH (NCT05767034)
- Testing
- Secukinumab 300 mg, Secukinumab 150 mg
- Where
- 132 sites in United States, Argentina and 24 more
- Volunteers
- 381 people
- Sponsor
- Novartis Pharmaceuticals
Giant Cell Arteritis
TARGET GCAT Registry
A longitudinal post-marketing surveillance registry nested within the UK GCA Consortium that assesses the effectiveness and safety of tocilizumab in controlling refractory or relapsing forms of GCA in patients who require…
- Trial name
- NCT04049071
- Where
- 34 sites in United Kingdom
- Volunteers
- 80 people
- Sponsor
- University of Leeds
Polymyalgia Rheumatica
Abatacept in earLy Onset Polymyalgia Rheumatica: Study ALORS
Polymyalgia rheumatic (PMR) is a frequent inflammatory disease. It affects the elderly, with peak incidences at the age of 70 to 80 years; an age >50 years or older, is considered a criterion for the diagnosis.
- Trial name
- ALORS (NCT03632187)
- Testing
- Abatacept
- Where
- 5 sites in France
- Volunteers
- 34 people
- Sponsor
- University Hospital, Brest
Temporal Arteritis
Diagnostic Study of Temporal Arteritis
Despite a large and growing body of knowledge concerning the diagnosis of temporal arteritis, this potentially crippling disease still requires pathological diagnosis in practically every case.
- Trial name
- NCT01130857
- Volunteers
- 100 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Polymyalgia Rheumatica
Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse
Polymyalgia rheumatica (PMR) is prevalent among elderly. Untreated, it leads to major reduction in quality of life. Glucocorticoids are the cornerstone of treatment, but have drawbacks, warranting glucocorticoid sparing…
- Trial name
- REDUCE-PMR-2 (NCT05533164)
- Testing
- Rituximab
- Where
- Netherlands
- Volunteers
- 174 people
- Sponsor
- Sint Maartenskliniek
Giant Cell Arteritis, Takayasu's Arteritis
Reproductive Health in Men and Women With Vasculitis
The purpose of this study is to learn about reproductive health, including fertility and pregnancies, in people with vasculitis.
- Conditions
- Giant Cell Arteritis, Takayasu's Arteritis, Polyarteritis Nodosa, Wegener's Granulomatosis
- Trial name
- NCT02176070
- Where
- United States
- Volunteers
- 467 people
- Sponsor
- University of South Florida
Horton Disease
Velocimetric Study of Temporal Arteries in Patients With Horton Disease Using Scan-Doppler
The use of ultrasonography in detecting giant cell arteritis ( GCA) is emerging. Currently, temporal biopsy is the gold standard to diagnose GCA but studies have shown the interest to use B mode ultrasonography.
- Trial name
- VELHOR (NCT03360162)
- Where
- France
- Volunteers
- 46 people
- Sponsor
- University Hospital, Brest
Polymyalgia Rheumatica, Inflammatory Diseases
A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica
The study is a two-week, single-blinded, double-dummy, randomized, active-controlled, parallel group design, with a follow-up period up to a total study duration of 6-month, non-randomized, open-label phase to monitor safety…
- Trial name
- NCT01364389
- Testing
- AIN457, ACZ885, Prednisone
- Where
- 6 sites in United States, Germany and 2 more
- Volunteers
- 16 people
- Sponsor
- Novartis Pharmaceuticals
Polymyalgia Rheumatica (PMR), Giant Cell Arteritis (GCA)
Predictive Factors for Treatment Response in Patients With Newly-diagnosed Polymyalgia Rheumatica and Giant Cell Arteritis
This prospective study is to explore different predictive factors for response to steroid treatment in patients with PMR and/or GCA.
- Trial name
- NCT05479448
- Testing
- Data collection for cellular analyses (Immune subset composition, GCR expression, in vitro steroid responsiveness), Data collection for exploratory analyses of endogenous steroid hormones, Data collection for correlation between clinical defined and lab defined GC responsivness
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- University Hospital, Basel, Switzerland
Giant Cell Arteritis (GCA)
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)
This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell arteritis (GCA)
- Trial name
- GCAptAIN (NCT04930094)
- Testing
- Secukinumab 300 mg, Secukinumab 150 mg
- Where
- 104 sites in United States, Argentina and 25 more
- Volunteers
- 354 people
- Sponsor
- Novartis Pharmaceuticals